Breast cancer lung metastasis treated with a minimally invasive freezing procedure
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- HER2-positive; ER-negative
- Sex
- Female
- Spread to
- lungs
- Treatment
- chemotherapy, targeted therapy, surgery, radiation, cryoablation and surveillance
- Outcome
- Stable / No Progression
Treatment course, step by step
- Neoadjuvant epirubicin/cyclophosphamide, then weekly paclitaxel with trastuzumab and pertuzumab; bilateral lumpectomy, radiation and 1 year of trastuzumab.
- Recurrence was treated with vinorelbine/trastuzumab/pertuzumab, mastectomy, lung resections, T-DM1, stereotactic radiation and later percutaneous cryoablation of a solitary lung metastasis.
What happened, in summary
A woman in her 60s was diagnosed with a 42 mm HER2-positive, estrogen receptor-negative invasive ductal carcinoma in the left breast and ductal carcinoma in situ in the right breast. She received epirubicin and cyclophosphamide, followed by weekly paclitaxel with trastuzumab and pertuzumab. This was followed by bilateral lumpectomy, radiation, and 1 year of trastuzumab.
The left-breast cancer later returned and spread to both lungs. Over several years, she received vinorelbine with trastuzumab and pertuzumab, mastectomy, several lung resections, T-DM1, and stereotactic radiation. Eventually, only a single 7 mm metastasis remained close to the surface of the lung. Further surgery was not considered feasible.
She underwent outpatient CT-guided cryoablation. A probe was placed through the chest wall into the small lung lesion, which was frozen under image guidance. The procedure lasted about 40 minutes. She went home 2 hours later and did not require overnight admission. Mild coughing of blood stopped within 2 days.
She did not receive systemic therapy after the ablation. PET-CT at 3, 6, 9, and 12 months showed no growth of the treated area and no new lesions. Her disease therefore remained stable without progression for at least 1 year after the procedure. The result supported local treatment for a carefully selected solitary lung metastasis.
Cryoablation was chosen because the lesion was small, isolated, and close to the pleural surface. It offered local control without another lung operation or an immediate return to systemic therapy. No systemic therapy was given during the 12-month post-ablation surveillance period.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Stage 4 HER2 Positive Breast Cancer 53 stories
- HER2 Positive Breast Cancer 136 stories
- Chemotherapy for Breast Cancer 726 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer